跳至主要内容
临床试验/NCT01466244
NCT01466244已完成不适用

PTEN Determination in Squamous Cell Cancer of The Head and Neck Treated on E5397, A Randomized Phase III Trial of Cisplatin Plus Placebo Versus Cisplatin Plus C225 (Cetuximab) in Metastatic/Recurrent Head and Neck Cancer

Eastern Cooperative Oncology Group0 个研究点目标入组 42 人开始时间: 2011年11月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
42
主要终点
Cetuximab activity as reflected in RR

研究概览

简要总结

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in patients with metastatic or recurrent head and neck cancer treated with cisplatin and cetuximab on ECOG-E5397.

详细描述

OBJECTIVES:

Primary

  • Compare cetuximab activity, as reflected in response rate (RR), in PTEN-deficient and PTEN-expressing cancers.

Secondary

  • Examine RR, progression-free survival (PFS), and overall survival (OS) in PTEN-deficient and PTEN-expressing cancers, by treatment arm.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Cetuximab activity as reflected in RR

时间窗: 1 year

次要结局

未报告次要终点

研究者

申办方类型
Network
责任方
Sponsor

相似试验

Biomarkers in Patients With Metastatic or Recurrent... | 临床试验